[go: up one dir, main page]

WO2019078634A3 - Composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine ptp4a1 - Google Patents

Composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine ptp4a1 Download PDF

Info

Publication number
WO2019078634A3
WO2019078634A3 PCT/KR2018/012322 KR2018012322W WO2019078634A3 WO 2019078634 A3 WO2019078634 A3 WO 2019078634A3 KR 2018012322 W KR2018012322 W KR 2018012322W WO 2019078634 A3 WO2019078634 A3 WO 2019078634A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin resistance
fatty liver
prevention
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/012322
Other languages
English (en)
Korean (ko)
Other versions
WO2019078634A2 (fr
Inventor
민정기
박종길
황병태
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2019078634A2 publication Critical patent/WO2019078634A2/fr
Publication of WO2019078634A3 publication Critical patent/WO2019078634A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine PTP4A1 ou un polynucléotide codant pour la protéine PTP4A1. La surexpression de la protéine PTP4A1 a pour effet d'atténuer la résistance à l'insuline et de supprimer la production de foie gras de sorte que la protéine PTP4A1 selon la présente invention peut être efficacement utilisée à titre d'agent thérapeutique dans le domaine des syndromes métaboliques.
PCT/KR2018/012322 2017-10-18 2018-10-18 Composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine ptp4a1 Ceased WO2019078634A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0135408 2017-10-18
KR1020170135408A KR102496229B1 (ko) 2017-10-18 2017-10-18 Ptp4a1 단백질을 포함하는 인슐린 저항성 또는 지방간의 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2019078634A2 WO2019078634A2 (fr) 2019-04-25
WO2019078634A3 true WO2019078634A3 (fr) 2019-06-20

Family

ID=66174150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012322 Ceased WO2019078634A2 (fr) 2017-10-18 2018-10-18 Composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine ptp4a1

Country Status (2)

Country Link
KR (1) KR102496229B1 (fr)
WO (1) WO2019078634A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102216646B1 (ko) * 2018-11-23 2021-02-17 차의과학대학교 산학협력단 중간엽 줄기세포를 포함하는 지방 생성을 억제하기 위한 조성물
KR20240177783A (ko) * 2023-06-19 2024-12-30 (주) 플라바이오로직스 펩타이드 도입에 따른 중간엽 줄기세포의 제조방법 및 치료용 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
WO2010040571A2 (fr) * 2008-10-10 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
KR20160000041A (ko) * 2014-06-23 2016-01-04 주식회사 바이오포트코리아 인삼 열매 추출물을 유효성분으로 포함하는 당뇨병 또는 당뇨 합병증 예방, 개선 또는 치료용 조성물
KR20160084528A (ko) * 2015-01-05 2016-07-14 서울대학교산학협력단 제2형 당뇨병의 조기 진단을 위한 단백질 바이오 마커

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949394B (zh) 2015-08-19 2021-07-30 韩国生命工学研究院 黑豆叶提取物在制备用于预防或治疗代谢综合征的药物中的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
WO2010040571A2 (fr) * 2008-10-10 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
KR20160000041A (ko) * 2014-06-23 2016-01-04 주식회사 바이오포트코리아 인삼 열매 추출물을 유효성분으로 포함하는 당뇨병 또는 당뇨 합병증 예방, 개선 또는 치료용 조성물
KR20160084528A (ko) * 2015-01-05 2016-07-14 서울대학교산학협력단 제2형 당뇨병의 조기 진단을 위한 단백질 바이오 마커

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HWANG, BYUNG TAE: "The Multifunctional Roles of PTP4A1 in Angiogenesis and Insulin Resistance", UNIV. OF SCIENCE AND TECHNOLOGY, LIFE SCIENCE BIOMOLECULE SCIENCE, August 2017 (2017-08-01), pages 47, 50, 51, 67 *

Also Published As

Publication number Publication date
WO2019078634A2 (fr) 2019-04-25
KR20190043397A (ko) 2019-04-26
KR102496229B1 (ko) 2023-02-06

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
WO2019006005A3 (fr) Procédés et compositions pour le traitement du mélanome
EP3111931A4 (fr) Composition pharmaceutique pour le traitement du cancer contenant du gossypol et de la phénformine en tant que principes actifs
MX378422B (es) Uso de empagliflozina para el tratamiento de trastornos metabòlicos, la prevenciòn, y para la reducciòn del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
WO2014190163A3 (fr) Polythérapie pour mds
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
PH12017501120A1 (en) Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes
HK1216300A1 (zh) 作为crac通道抑制剂的基於吡唑基的甲醯胺i
WO2016178510A3 (fr) Composition pharmaceutique pour la prévention ou le traitement de la leucémie résistant au gleevec, contenant, comme principe actif, du ginsénoside f1 ou rg3
WO2019078634A3 (fr) Composition pharmaceutique pour la prévention ou le traitement de la résistance à l'insuline ou du foie gras, comprenant une protéine ptp4a1
EP3277269A4 (fr) Méthodes de prévention et de traitement du syndrome cardiométabolique et compositions utilisées pour ces dernières
MX2016012127A (es) Ostreolisina, variante de la misma funcionalmente relacionada, extracto que comprende ostreolisina y usos de los mismos.
HK1216301A1 (zh) 作为crac通道抑制剂的基於吡唑基的甲醯胺ii
WO2020022975A3 (fr) Nouvelles compositions pharmaceutiques dans le traitement de la bpco
EP3881845A3 (fr) Combinaison avec du trazodone et de la gabapentine pour le traitement de la douleur
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
IN2013MU03428A (fr)
MX2023005681A (es) Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18868993

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18868993

Country of ref document: EP

Kind code of ref document: A2